Pain Management in Erythromelalgia: A Systematic Review and Graded Appraisal Across Etiological Subtypes
Abstract
INTRODUCTION: Erythromelalgia is a rare disorder characterised by burning pain, erythema and increased skin temperature in the extremities. Its pathophysiological heterogeneity, together with variable treatment responses, complicates management in the absence of evidence-based guidelines. This systematic review appraised pain-management strategies across reported aetiological subtypes. DATABASES AND DATA TREATMENT: Following PRISMA 2020 guidelines, the review was registered in PROSPERO (CRD420251232074). PubMed, Embase, the Cochrane Library and ClinicalTrials.gov were searched for studies published or registered between 1 January 2000 and 30 April 2026. Randomised controlled trials, non-randomised interventional studies, cohort studies and case series were eligible; non-randomised studies required at least five individuals. Risk of bias was assessed using Joanna Briggs Institute tools and certainty of evidence using GRADE. RESULTS: Of 3372 records, 25 studies reporting 591 individuals were included. Aetiological subtype was reported for 277 individuals (46.9%). Mechanistic and aetiological characterisation varied substantially across domains, with haematological data available for 72.6% and SCN9A status for 19.0% of the overall population. Moderate-certainty evidence supported aspirin in myeloproliferative neoplasm-associated erythromelalgia. Low-certainty evidence suggested benefit from mexiletine and carbamazepine in primary erythromelalgia, as well as from prostaglandin analogues, corticosteroids, selected topical therapies and sympathetic interventions in specific contexts. Evidence for selective Naᵥ1.7 inhibitors and most other interventions was of very low certainty. CONCLUSIONS: Treatment-response patterns in better-characterised populations suggest that aetiology and underlying mechanisms may be relevant to treatment selection. However, this mechanism-informed approach remains hypothesis-generating and requires prospective validation through systematic aetiological and mechanistic characterisation. SIGNIFICANCE STATEMENT: This systematic review provides a comprehensive, graded evaluation of the full spectrum of pain-management strategies in erythromelalgia, including systemic, topical, interventional and non-pharmacological approaches, across reported aetiological subtypes. Integrating risk-of-bias appraisal and GRADE certainty ratings, it identifies moderate-certainty evidence for aspirin in myeloproliferative neoplasm-associated disease and low-certainty evidence for conventional sodium-channel blockers in selected primary forms, while evidence for other interventions remains low or very low. These patterns suggest that aetiology may inform treatment selection, but require prospective validation.
Related
- Prediction models for venous thromboembolism in pediatric patients: A protocol for systematic review and critical appraisal
- Molecular Confirmation of Neospora caninum as the Etiological Agent of Abortion in a Dairy Cattle Herd in Qazvin Province, Iran.
- Spontaneous native–non-native tree mixtures worldwide: a systematic map of research patterns, with knowledge gaps and management implications
- Etiological characteristics and genotypes of Mycoplasma pneumoniae infection in children in Baoding from 2022 to 2024
- Distribution, major threats, and management methods of maple tree species in temperate forests: a systematic review and meta-analysis.
BibTeX
@article{racca2026pain,
title = {{Pain Management in Erythromelalgia: A Systematic Review and Graded Appraisal Across Etiological Subtypes}},
author = {Camille Racca and Sarah Berthelot and Julia Franken and Marion Licois and Ada Du Pasquier and Ihssene Djidjeli and Laura Esteve and Eric Serra and Xavier Moisset},
journal = {European Journal of Pain},
year = {2026},
month = sep,
doi = {10.1002/ejp.70368},
url = {https://hal.science/hal-05794359v1},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Pain Management in Erythromelalgia: A Systematic Review and Graded Appraisal Across Etiological Subtypes
AU - Camille Racca
AU - Sarah Berthelot
AU - Julia Franken
AU - Marion Licois
AU - Ada Du Pasquier
AU - Ihssene Djidjeli
AU - Laura Esteve
AU - Eric Serra
AU - Xavier Moisset
PY - 2026
DA - 2026/09/04
JO - European Journal of Pain
DO - 10.1002/ejp.70368
UR - https://hal.science/hal-05794359v1
AB - INTRODUCTION: Erythromelalgia is a rare disorder characterised by burning pain, erythema and increased skin temperature in the extremities. Its pathophysiological heterogeneity, together with variable treatment responses, complicates management in the absence of evidence-based guidelines. This systematic review appraised pain-management strategies across reported aetiological subtypes. DATABASES AND DATA TREATMENT: Following PRISMA 2020 guidelines, the review was registered in PROSPERO (CRD420251232074). PubMed, Embase, the Cochrane Library and ClinicalTrials.gov were searched for studies published or registered between 1 January 2000 and 30 April 2026. Randomised controlled trials, non-randomised interventional studies, cohort studies and case series were eligible; non-randomised studies required at least five individuals. Risk of bias was assessed using Joanna Briggs Institute tools and certainty of evidence using GRADE. RESULTS: Of 3372 records, 25 studies reporting 591 individuals were included. Aetiological subtype was reported for 277 individuals (46.9%). Mechanistic and aetiological characterisation varied substantially across domains, with haematological data available for 72.6% and SCN9A status for 19.0% of the overall population. Moderate-certainty evidence supported aspirin in myeloproliferative neoplasm-associated erythromelalgia. Low-certainty evidence suggested benefit from mexiletine and carbamazepine in primary erythromelalgia, as well as from prostaglandin analogues, corticosteroids, selected topical therapies and sympathetic interventions in specific contexts. Evidence for selective Naᵥ1.7 inhibitors and most other interventions was of very low certainty. CONCLUSIONS: Treatment-response patterns in better-characterised populations suggest that aetiology and underlying mechanisms may be relevant to treatment selection. However, this mechanism-informed approach remains hypothesis-generating and requires prospective validation through systematic aetiological and mechanistic characterisation. SIGNIFICANCE STATEMENT: This systematic review provides a comprehensive, graded evaluation of the full spectrum of pain-management strategies in erythromelalgia, including systemic, topical, interventional and non-pharmacological approaches, across reported aetiological subtypes. Integrating risk-of-bias appraisal and GRADE certainty ratings, it identifies moderate-certainty evidence for aspirin in myeloproliferative neoplasm-associated disease and low-certainty evidence for conventional sodium-channel blockers in selected primary forms, while evidence for other interventions remains low or very low. These patterns suggest that aetiology may inform treatment selection, but require prospective validation.
SN - 1090-3801
SN - 1532-2149
ER -